JP7458973B2 - 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用 - Google Patents

新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用 Download PDF

Info

Publication number
JP7458973B2
JP7458973B2 JP2020526685A JP2020526685A JP7458973B2 JP 7458973 B2 JP7458973 B2 JP 7458973B2 JP 2020526685 A JP2020526685 A JP 2020526685A JP 2020526685 A JP2020526685 A JP 2020526685A JP 7458973 B2 JP7458973 B2 JP 7458973B2
Authority
JP
Japan
Prior art keywords
seq
antibody molecule
antibody
treg
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020526685A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020528765A (ja
JP2020528765A5 (https=
Inventor
フレンデウス ビョルン
モルテンソン リンダ
センリヒ モニカ
テイゲ イングリッド
ベーアス スティーブン
アル－シャムクハニ アイメン
グレイ ジュリエット
グレニー マーティン
Original Assignee
バイオインベント インターナショナル アクティエボラーグ
キャンサー リサーチ テクノロジー リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオインベント インターナショナル アクティエボラーグ, キャンサー リサーチ テクノロジー リミティド filed Critical バイオインベント インターナショナル アクティエボラーグ
Publication of JP2020528765A publication Critical patent/JP2020528765A/ja
Publication of JP2020528765A5 publication Critical patent/JP2020528765A5/ja
Priority to JP2023106715A priority Critical patent/JP2023129433A/ja
Application granted granted Critical
Publication of JP7458973B2 publication Critical patent/JP7458973B2/ja
Priority to JP2025116576A priority patent/JP2025157343A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020526685A 2017-07-26 2018-07-26 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用 Active JP7458973B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023106715A JP2023129433A (ja) 2017-07-26 2023-06-29 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用
JP2025116576A JP2025157343A (ja) 2017-07-26 2025-07-10 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1712032.0A GB201712032D0 (en) 2017-07-26 2017-07-26 Antibodies and uses thereof
GB1712032.0 2017-07-26
PCT/EP2018/070359 WO2019020774A2 (en) 2017-07-26 2018-07-26 NOVEL ANTIBODIES AND COMBINED USE OF ANTIBODY THAT INDUCES TREG DEPLOYMENT AND AN IMMUNOSTIMULATOR ANTIBODY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023106715A Division JP2023129433A (ja) 2017-07-26 2023-06-29 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用

Publications (3)

Publication Number Publication Date
JP2020528765A JP2020528765A (ja) 2020-10-01
JP2020528765A5 JP2020528765A5 (https=) 2021-07-26
JP7458973B2 true JP7458973B2 (ja) 2024-04-01

Family

ID=59771732

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020526685A Active JP7458973B2 (ja) 2017-07-26 2018-07-26 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用
JP2023106715A Pending JP2023129433A (ja) 2017-07-26 2023-06-29 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用
JP2025116576A Pending JP2025157343A (ja) 2017-07-26 2025-07-10 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023106715A Pending JP2023129433A (ja) 2017-07-26 2023-06-29 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用
JP2025116576A Pending JP2025157343A (ja) 2017-07-26 2025-07-10 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用

Country Status (8)

Country Link
US (2) US11447549B2 (https=)
EP (1) EP3658587A2 (https=)
JP (3) JP7458973B2 (https=)
CN (1) CN111108124B (https=)
AU (1) AU2018305209B2 (https=)
CA (1) CA3070290A1 (https=)
GB (1) GB201712032D0 (https=)
WO (1) WO2019020774A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220032642A (ko) * 2016-04-07 2022-03-15 캔써 리서치 테크놀로지 리미티드 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
AU2019312200B2 (en) 2018-07-23 2024-11-14 Heidelberg Pharma Research Gmbh Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy
PL3623798T3 (pl) * 2018-09-13 2022-03-28 Euroimmun Medizinische Labordiagnostika Ag Sposób i urządzenie do wykrywania i przedstawiania obrazu immunofluorescencyjnego próbki biologicznej
SG11202110287QA (en) 2019-04-24 2021-10-28 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
US11246906B2 (en) * 2019-06-11 2022-02-15 Alkermes Pharma Ireland Limited Compositions and methods for subcutaneous administration of cancer immunotherapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3122779B1 (en) * 2014-03-24 2019-05-22 Cancer Research Technology Limited Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof
WO2015188047A1 (en) * 2014-06-06 2015-12-10 University Of Maryland, Baltimore ANTI-CD-137 MONOCLONAL ANTIBODIES WITH DISTINCT FcγR BINDING ABILITIES FOR TREATMENT OF CANCER OR AUTOIMMUNITY
US20170247455A1 (en) * 2014-08-22 2017-08-31 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
CN107207594B (zh) 2014-12-23 2019-05-07 百时美施贵宝公司 针对tigit的抗体
TWI719970B (zh) 2015-03-23 2021-03-01 美商永斯醫療股份有限公司 針對ｉｃｏｓ之抗體
HK1251474A1 (zh) * 2015-06-08 2019-02-01 豪夫迈‧罗氏有限公司 使用抗ox40抗体和pd-1轴结合拮抗剂治疗癌症的方法
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
KR20220032642A (ko) * 2016-04-07 2022-03-15 캔써 리서치 테크놀로지 리미티드 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체
BR112019025913A2 (pt) 2017-06-09 2020-06-30 Glaxosmithkline Intellectual Property Development Limited métodos para tratar câncer em um paciente em necesssidade do mesmo e para produzir um anticorpo, anticorpo anti-icos ou fragmento de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou fragmento de ligação ao antígeno do mesmo, uso de um anticorpo anti-icos ou porção de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou porção de ligação ao antígeno do mesmo na fabricação de um medicamento, polinucleotídeo que codifica um anticorpo, vetor, e, célula hospedeira.

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
M.Remer, et al.，Cancer Immunology Research，2016年，Vol.4, No.11, Supp.，Abstract B046
S.Chen, et al.，Cancer Immunology Research，2015年，Vol.3(2)，p.149-160
Y.Shindo, et al.，ANTICANCER RESEARCH，2015年，Vol.35，p.129-136

Also Published As

Publication number Publication date
JP2020528765A (ja) 2020-10-01
CN111108124B (zh) 2024-09-03
JP2025157343A (ja) 2025-10-15
AU2018305209A1 (en) 2020-02-06
US20230058227A1 (en) 2023-02-23
AU2018305209B2 (en) 2025-06-26
GB201712032D0 (en) 2017-09-06
CN111108124A (zh) 2020-05-05
US20200207855A1 (en) 2020-07-02
JP2023129433A (ja) 2023-09-14
EP3658587A2 (en) 2020-06-03
WO2019020774A2 (en) 2019-01-31
US11447549B2 (en) 2022-09-20
WO2019020774A3 (en) 2019-05-02
CA3070290A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
US20230265200A1 (en) Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion
JP7458973B2 (ja) 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用
US20250163152A1 (en) Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
CN110248678A (zh) 调节car-t细胞的方法
JP2020506697A (ja) 改善された抗体結合ｔ細胞受容体構築物およびその治療用途
BR112021007995A2 (pt) molécula de anticorpo antagonista, sequência de nucleotídeos isolada, plasmídeo, vírus, célula, uso de uma molécula de anticorpo, composição farmacêutica, método para tratar câncer ou uma infecção causada por um patógeno intracelular em um paciente
JP2022537068A (ja) 抗ａｌｐｐ ｃａｒ－ｔ細胞療法
CA3170020A1 (en) Anti-hpv t cell receptors and engineered cells
EP3617230A1 (en) Novel antibodies and nucleotide sequences, and uses thereof
RU2829587C2 (ru) Новые молекулы антагонистических анти-tnfr2-антител
RU2800035C2 (ru) Новая комбинация антител и ее применение
CN119661712A (zh) 特异性结合tnfr2的抗体及其应用
HK40110145A (zh) 新型拮抗性抗tnfr2抗体分子
HK40109442A (zh) 新型拮抗性抗tnfr2抗体分子
HK40050308B (zh) 新型拮抗性抗tnfr2抗体分子
HK1262659A1 (en) Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion
NZ786026A (en) Anti CD25 Fc gamma receptor bispecific antibodies for tumor specific cell depletion

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210610

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230629

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240312

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240319

R150 Certificate of patent or registration of utility model

Ref document number: 7458973

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150